[|Although I agree that in different families with psoriasis the genes
involved are different, form the main point of the genetics in
psoriasis should be made more clear: psoriasis is a polygenic disease,
i.e. within one patient there is a set of genes responsible for the
predisposition to psoriasis, which is different from that of another
patient, even in the same family.|auteur195]
[|The genetic aspects of psoriasis are well reviewed. From a personal perspective, having had the pleasure of working with Dr. Anne Bowcock, the discoverer of PSORS2 gene on chromosome 17 in 1994, for the past 14 years, I have always felt that the various phenotypic manifestations of psoriasis need to be carefully genotyped. Time needs to be spent in evaluating the genetics of these various psoriatic subtypes. In addition, there are obviously genetic associations with other immune-mediated diseases such as Crohn’s disease. Finally, is psoriatic arthritis truly a variation of psoriasis vulgaris as to date the genetics of the various forms of psoriatic arthritis remains to be fully elucidated. With the complexities of the phenotypic expressions in the skin, as well as the multiple variations of psoriatic arthritis, it is likely that the full genetic spectrum of psoriasis may take years to unravel.|auteur215]
Psoriasis is associated with familial involvement in 30 to 40% of cases. In patients whose illness starts during childhood, a strong linkage is noted between the disorder and certain HLA groups (CW6, CW7 and, less so, HLA B13, B17, B37, B38, B57, DR4 and DR7). In homozygous twins, one twin being affected goes hand in hand with the other being affected in 70% of cases. This concordance illustrates at once the existence of genetic predispositions and the triggering role of the environment.
By studying large families with psoriasis, it has been possible to detect chromosomal regions associated with the disease. These regions vary from one family to another, but three regions have been identified with some frequency by different teams: PSOR S1 on chromosome 6p, PSOR S2 on chromosome 17q and PSOR S3 on chromosome 4. Other regions have been identified: 1q21, 3q21, 4qter, 14q31-q32, 17q24-q25, 19p13.3 and 20p. Some of these regions represent genes of interest, like corneodesmosine, the key protein in desquamation, or a gene associated with the Crohn disease. Some of these chromosomal regions, particularly region 17q24-q25 (PSORS2), are currently arousing a quite special interest following the work of A.M. Bowcock. The genes in this region encode for a set of genes of the superfamily of immunoglobulins. Recently, in one psoriatic family, this researcher identified a gene and the corresponding protein that might be associated with the expression of the disease.
Whatever may be the interest of this research, one must not forget that the genes involved are probably different from one family to another, that most psoriasis are not familial and that there is no psoriasis gene, as some unscrupulous researchers have made believe to some families. Psoriasis must be clearly explained as being greatly different from the monogenic genetic diseases. In fact, given certain environmental conditions, it is likely that all the genotypes associated directly or indirectly with a significant increase of cytokinic expression in response to aggressions are capable of expressing themselves through different forms of psoriasis. It would be particularly interesting to be able to define groups of patients that belong to homogenous clinical phenotypes.
- 2019/10/29 Focus on...World Psoriasis Day 2019
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat. 2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol.. 2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)see on pubmed
Prohibitin 1 interacts with signal transducer and activator of transcription 3 in T-helper 17 cells.
Immunol. Lett.. 2020 Mar , 219:8-14.
T-helper 17 (Th17) cells are involved in the occurrence and development of several inflammation-associated diseases. Interleukin (IL)-17, the main cytokine secreted by differentiated Th17 cells, mediates immunoreactions and plays important roles in immunological diseases, including psoriasis, rheumatic arthritis, and inflammatory bowel disease. The maturation and stabilization of the differentiated Th17 cell phenotype are associated with the expression of IL-17A, which is induced by the (...)see on pubmed
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat. 2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol. 2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).see on pubmed